163 related articles for article (PubMed ID: 18593999)
61. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
62. Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.
Walter T; Planchard D; Bouledrak K; Scoazec JY; Souquet PJ; Dussol AS; Guigay J; Hervieu V; Berdelou A; Ducreux M; Arpin D; Lombard-Bohas C; Baudin E
Lung Cancer; 2016 Jun; 96():68-73. PubMed ID: 27133753
[TBL] [Abstract][Full Text] [Related]
63. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.
Goldstein D; Mitchell P; Michael M; Beale P; Friedlander M; Zalcberg J; White S; Clarke S
Br J Cancer; 2005 Mar; 92(5):832-7. PubMed ID: 15756253
[TBL] [Abstract][Full Text] [Related]
64. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
Raspagliesi F; Zanaboni F; Vecchione F; Hanozet F; Scollo P; Ditto A; Grijuela B; Fontanelli R; Solima E; Spatti G; Scibilia G; Kusamura S
Oncology; 2004; 67(5-6):376-81. PubMed ID: 15713993
[TBL] [Abstract][Full Text] [Related]
65. The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.
Mosconi S; Cascinu S; Zaniboni A; Catalano V; Giordani P; Beretta GD; Martignoni G; Pancera G; Baldelli AM; Poletti P; Curti C; Labianca R
Tumori; 2000; 86(6):465-9. PubMed ID: 11218187
[TBL] [Abstract][Full Text] [Related]
66. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
[TBL] [Abstract][Full Text] [Related]
67. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Gourgou-Bourgade S; Bascoul-Mollevi C; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Boige V; Bérille J; Conroy T
J Clin Oncol; 2013 Jan; 31(1):23-9. PubMed ID: 23213101
[TBL] [Abstract][Full Text] [Related]
68. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
69. Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
Chang AY; Lopes G; Hsin KW; Lim R; Fong FK; Wong J
Clin Colorectal Cancer; 2007 Sep; 6(9):646-51. PubMed ID: 17945037
[TBL] [Abstract][Full Text] [Related]
70. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
El-Hadaad HA; Wahba HA
J Gastrointest Cancer; 2013 Sep; 44(3):313-7. PubMed ID: 23606201
[TBL] [Abstract][Full Text] [Related]
71. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.
Raderer M; Hejna MH; Valencak JB; Kornek GV; Weinländer GS; Bareck E; Lenauer J; Brodowicz T; Lang F; Scheithauer W
Oncology; 1999 Apr; 56(3):177-80. PubMed ID: 10202270
[TBL] [Abstract][Full Text] [Related]
72. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
73. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
[TBL] [Abstract][Full Text] [Related]
74. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
[TBL] [Abstract][Full Text] [Related]
75. Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.
Gunturu KS; Meehan KR; Mackenzie TA; Crocenzi TS; McDermott D; Usherwood EJ; Margolin KA; Crosby NA; Atkins MB; Turk MJ; Ahonen C; Fuse S; Clark JI; Fisher JL; Noelle RJ; Ernstoff MS
J Clin Oncol; 2010 Mar; 28(7):1196-202. PubMed ID: 20124177
[TBL] [Abstract][Full Text] [Related]
76. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Haller DG; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Gilberg F; Rittweger K; Schmoll HJ
J Clin Oncol; 2011 Apr; 29(11):1465-71. PubMed ID: 21383294
[TBL] [Abstract][Full Text] [Related]
77. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
[TBL] [Abstract][Full Text] [Related]
78. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
79. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Schmoll HJ; Cartwright T; Tabernero J; Nowacki MP; Figer A; Maroun J; Price T; Lim R; Van Cutsem E; Park YS; McKendrick J; Topham C; Soler-Gonzalez G; de Braud F; Hill M; Sirzén F; Haller DG
J Clin Oncol; 2007 Jan; 25(1):102-9. PubMed ID: 17194911
[TBL] [Abstract][Full Text] [Related]
80. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
